Objective: The aim of this study was to investigate and compare the treatment methods of large size oroantral defects (OADs) and their clinical outcomes.
Material and Methods: The patients who referred our clinic between 2017 and 2023 suffering from oroantral fistula (OAF) and the cases which was occurred oroantral communication (OAC) larger than 5mm during oral procedures were included in the study. The size, type and cause of OAD, treatment method, the patient’s demographic data was recorded. VAS scale, analgesic requirement, the edema, and mouth opening measurements were obtained from preoperative day and postoperative records at 3, 7, 10 days after surgery.
Results: 23 patient (8 OAF, 15 OAC) was included in this study. 9 of them was treated with buccal advancement flap (BAF), 10 with buccal fat pad (BFP) and 4 with press-fit technique. No problem was occurred at the healing process. Only in one patient BFP application was failed, and after 2 months second surgery was performed, and the area was fully covered. According to postoperative clinical outcomes, any statistically significance wasn’t observed between groups in the terms of vas scale, analgesic requirement, edema and trismus at any timepoint (p 0.05). Although there was insignificance at all parameters between treatment groups, VAS scale and analgesic requirement was less than BAF and BFP in press fit.
Conclusion: BAF, BFP and press-fit methods are reliable and well-known techniques for OAD management, however, further clinical studies with larger sample sizes are needed to create treatment algorithm for OAD.
Oroantral communication oroantral fistula buccal flap buccal fat pad press-fit
Birincil Dil | İngilizce |
---|---|
Konular | Ağız, Yüz ve Çene Cerrahisi |
Bölüm | Araştırma Makalesi |
Yazarlar | |
Erken Görünüm Tarihi | 12 Kasım 2024 |
Yayımlanma Tarihi | |
Gönderilme Tarihi | 1 Temmuz 2024 |
Kabul Tarihi | 25 Eylül 2024 |
Yayımlandığı Sayı | Yıl 2025 |
Current Research in Dental Sciences is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.